Lecanemab is an antibody therapy designed to slow cognitive decline in early Alzheimer’s disease. It targets and removes sticky amyloid plaques in the brain. Administered as a biweekly intravenous infusion, it benefits adults with mild cognitive impairment or mild dementia confirmed through biomarker testing. Regular monitoring for side effects like brain swelling is essential.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends